FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W5483291> ?p ?o ?g. }

• W5483291 endingPage "234" @default.
• W5483291 startingPage "225" @default.
• W5483291 abstract "Longer-term pharmacologic studies for insomnia in older individuals are sparse.To evaluate the efficacy and safety of 12 weeks of nightly eszopiclone in elderly outpatients with insomnia.Participants (65-85 years) met DSM-IV-TR criteria for insomnia with total sleep times (TST) < or = 6 h, and wake time after sleep onset (WASO) > or = 45 min. Participants were randomized to 12 weeks of eszopiclone 2 mg (n = 194) or placebo (n = 194), followed by a 2-week single-blind placebo run-out. Subject-reported measures of sleep (sTST, sleep latency [sSL], sWASO) and daytime function (alertness, concentration, wellbeing, ability to function) were assessed. AEs were monitored.Subjects treated with 2 mg eszopiclone slept longer at night on average and at every individual time point compared to baseline than placebo subjects, as measured by TST over the 12-week double-blind period (P < 0.0001). Mean sTST over the double-blind period for eszopiclone-treated subjects was 360.08 min compared to 297.86 min at baseline, a mean change of 63.24 min. Over the double-blind period, eszopiclone-treated subjects also experienced a significantly greater improvement in sSL compared to placebo, with a mean decrease of 24.62 min versus a mean decrease of 19.92 min, respectively (P = 0.0014). Eszopiclone subjects also experienced a significantly greater decrease in WASO (mean decrease of 36.4 min) compared to placebo subjects (decrease of 14.8 min) (P < 0.0001). Post-discontinuation, sleep parameters were statistically improved versus baseline for eszopiclone (P-values < or = 0.01), indicating no rebound. The most common AEs (> or = 5%) were headache (eszopiclone 13.9%, placebo 12.4%), unpleasant taste (12.4%, 1.5%), and nasopharyngitis (5.7%, 6.2%).In this Phase IV trial of older adults with insomnia, eszopiclone significantly improved patient-reported sleep and daytime function relative to placebo. Improvements occurred within the first week and were maintained for 3 months, with no evidence of rebound insomnia following discontinuation. The 12 weeks of treatment were well tolerated.A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia; Registration #NCT00386334; URL - http://www.clinicaltrials.gov/ct2/show/NCT00386334?term=eszopiclone&rank=24" @default.
• W5483291 created "2016-06-24" @default.
• W5483291 creator A5011832419 @default.
• W5483291 creator A5020024835 @default.
• W5483291 creator A5042168269 @default.
• W5483291 creator A5052217756 @default.
• W5483291 creator A5054054268 @default.
• W5483291 creator A5064903239 @default.
• W5483291 creator A5081607221 @default.
• W5483291 creator A5087471581 @default.
• W5483291 date "2010-02-01" @default.
• W5483291 modified "2023-10-05" @default.
• W5483291 title "A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia" @default.
• W5483291 cites W1509106161 @default.
• W5483291 cites W1518386324 @default.
• W5483291 cites W1556900937 @default.
• W5483291 cites W1604022829 @default.
• W5483291 cites W1715752662 @default.
• W5483291 cites W1894310296 @default.
• W5483291 cites W1966475943 @default.
• W5483291 cites W2037926687 @default.
• W5483291 cites W2058713081 @default.
• W5483291 cites W2059703710 @default.
• W5483291 cites W2060446359 @default.
• W5483291 cites W2061885811 @default.
• W5483291 cites W2066580767 @default.
• W5483291 cites W2082850379 @default.
• W5483291 cites W2099661804 @default.
• W5483291 cites W2100700514 @default.
• W5483291 cites W2112715818 @default.
• W5483291 cites W2114531500 @default.
• W5483291 cites W2126386321 @default.
• W5483291 cites W2127024218 @default.
• W5483291 cites W2135791470 @default.
• W5483291 cites W2147942665 @default.
• W5483291 cites W2150225718 @default.
• W5483291 cites W2155139777 @default.
• W5483291 cites W2164658166 @default.
• W5483291 cites W2414400730 @default.
• W5483291 cites W27671986 @default.
• W5483291 cites W4255161776 @default.
• W5483291 doi "https://doi.org/10.1093/sleep/33.2.225" @default.
• W5483291 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2817909" @default.
• W5483291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20175406" @default.
• W5483291 hasPublicationYear "2010" @default.
• W5483291 type Work @default.
• W5483291 sameAs 5483291 @default.
• W5483291 citedByCount "71" @default.
• W5483291 countsByYear W54832912012 @default.
• W5483291 countsByYear W54832912013 @default.
• W5483291 countsByYear W54832912014 @default.
• W5483291 countsByYear W54832912015 @default.
• W5483291 countsByYear W54832912016 @default.
• W5483291 countsByYear W54832912017 @default.
• W5483291 countsByYear W54832912018 @default.
• W5483291 countsByYear W54832912019 @default.
• W5483291 countsByYear W54832912020 @default.
• W5483291 countsByYear W54832912021 @default.
• W5483291 countsByYear W54832912022 @default.
• W5483291 countsByYear W54832912023 @default.
• W5483291 crossrefType "journal-article" @default.
• W5483291 hasAuthorship W5483291A5011832419 @default.
• W5483291 hasAuthorship W5483291A5020024835 @default.
• W5483291 hasAuthorship W5483291A5042168269 @default.
• W5483291 hasAuthorship W5483291A5052217756 @default.
• W5483291 hasAuthorship W5483291A5054054268 @default.
• W5483291 hasAuthorship W5483291A5064903239 @default.
• W5483291 hasAuthorship W5483291A5081607221 @default.
• W5483291 hasAuthorship W5483291A5087471581 @default.
• W5483291 hasBestOaLocation W54832911 @default.
• W5483291 hasConcept C118552586 @default.
• W5483291 hasConcept C126322002 @default.
• W5483291 hasConcept C142724271 @default.
• W5483291 hasConcept C1513209611 @default.
• W5483291 hasConcept C15744967 @default.
• W5483291 hasConcept C197934379 @default.
• W5483291 hasConcept C204787440 @default.
• W5483291 hasConcept C27081682 @default.
• W5483291 hasConcept C2778715236 @default.
• W5483291 hasConcept C2778910407 @default.
• W5483291 hasConcept C2778996325 @default.
• W5483291 hasConcept C2779034229 @default.
• W5483291 hasConcept C2780930544 @default.
• W5483291 hasConcept C2781210498 @default.
• W5483291 hasConcept C2910380747 @default.
• W5483291 hasConcept C42219234 @default.
• W5483291 hasConcept C63759246 @default.
• W5483291 hasConcept C71924100 @default.
• W5483291 hasConceptScore W5483291C118552586 @default.
• W5483291 hasConceptScore W5483291C126322002 @default.
• W5483291 hasConceptScore W5483291C142724271 @default.
• W5483291 hasConceptScore W5483291C1513209611 @default.
• W5483291 hasConceptScore W5483291C15744967 @default.
• W5483291 hasConceptScore W5483291C197934379 @default.
• W5483291 hasConceptScore W5483291C204787440 @default.
• W5483291 hasConceptScore W5483291C27081682 @default.
• W5483291 hasConceptScore W5483291C2778715236 @default.
• W5483291 hasConceptScore W5483291C2778910407 @default.

• next